Titan Pharmaceuticals (NASDAQ:TTNP) Issues Quarterly Earnings Results

Titan Pharmaceuticals (NASDAQ:TTNP) released its earnings results on Friday. The specialty pharmaceutical company reported ($0.83) earnings per share for the quarter, Zacks reports.

Titan Pharmaceuticals Trading Up 1.3 %

NASDAQ TTNP traded up $0.04 on Friday, reaching $3.23. 17,499 shares of the company’s stock traded hands, compared to its average volume of 19,230. The stock has a 50 day moving average price of $3.74 and a 200-day moving average price of $4.99. Titan Pharmaceuticals has a fifty-two week low of $3.03 and a fifty-two week high of $14.80.

Analyst Upgrades and Downgrades

Separately, StockNews.com initiated coverage on shares of Titan Pharmaceuticals in a research note on Friday, December 27th. They set a “sell” rating on the stock.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.